These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 24984190)
1. Immuno-PET imaging of tumor endothelial marker 8 (TEM8). Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190 [TBL] [Abstract][Full Text] [Related]
2. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. Jagoda EM; Lang L; Bhadrasetty V; Histed S; Williams M; Kramer-Marek G; Mena E; Rosenblum L; Marik J; Tinianow JN; Merchant M; Szajek L; Paik C; Cecchi F; Raffensperger K; Jose-Dizon JM; Bottaro DP; Choyke P J Nucl Med; 2012 Oct; 53(10):1592-600. PubMed ID: 22917884 [TBL] [Abstract][Full Text] [Related]
3. ImmunoPET imaging of tissue factor expression in pancreatic cancer with Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831 [TBL] [Abstract][Full Text] [Related]
5. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763 [TBL] [Abstract][Full Text] [Related]
6. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647 [TBL] [Abstract][Full Text] [Related]
7. CD38 as a PET Imaging Target in Lung Cancer. Ehlerding EB; England CG; Jiang D; Graves SA; Kang L; Lacognata S; Barnhart TE; Cai W Mol Pharm; 2017 Jul; 14(7):2400-2406. PubMed ID: 28573863 [TBL] [Abstract][Full Text] [Related]
9. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273 [TBL] [Abstract][Full Text] [Related]
10. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091 [TBL] [Abstract][Full Text] [Related]
11. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts. Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168 [TBL] [Abstract][Full Text] [Related]
13. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis. Park BN; Kim GH; Ko SA; Shin GH; Lee SJ; An YS; Yoon JK Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412537 [TBL] [Abstract][Full Text] [Related]
14. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418 [TBL] [Abstract][Full Text] [Related]
15. Folate Receptor α-Targeted Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274 [TBL] [Abstract][Full Text] [Related]